Checking up on past Endpoints 11 winners: Who went public, who got bought and who’s still working

You win some, you lose some — that’s the risk of trying to predict the next hot biotechs.

Since 2018, the Endpoints 11 awards have identified …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Duchenne Drug Fails Confirmatory Trial; COVID Brain Changes; First-Seizure Clinics

Preliminary data showed that viltolarsen (Viltepso), an exon-skipping drug that won accelerated approval to treat Duchenne muscular dystrophy in 2020, failed a 48-week phase III

May 29, 2024

Numinus Partners With MAPS To Conduct Phase 1 MDMA Assisted Therapy Investigational Study

In a prelude to what is hoped will be regulatory approval of MDMA-assisted therapy in the U.S. and Canada, Numinus Wellness Inc. (TSE: NUMI) (OTCMKTS: NUMIF) has taken steps

June 15, 2023

Feasting for immunity: Study highlights foods that bolster your body’s defenses

Study reviews how certain foods, including fruits, vegetables, spices, and animal products, bolster the immune system. It details the immune-boosting properties of various foods and

November 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.